quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:04:55·65d
SECFiling
Halozyme Therapeutics Inc. logo

Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

HALO· Halozyme Therapeutics Inc.
Health Care
Original source

Companies

  • HALO
    Halozyme Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 4UpdateGoldman$56.00
  • Oct 14UpdateLeerink Partners$70.00
  • Aug 6UpdateMorgan Stanley$75.00
  • Jul 10UpdateGoldman$55.00
  • May 14UpdateMorgan Stanley$62.00
  • May 13UpdateLeerink Partners$47.00

Related

  • INSIDER16d
    SEC Form 4 filed by Torley Helen
  • PR16d
    Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
  • INSIDER21d
    SEC Form 4 filed by Ramsay David A
  • INSIDER21d
    SEC Form 4 filed by Torley Helen
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Halozyme Therapeutics Inc.
  • INSIDER31d
    SEC Form 3 filed by new insider Ramsay David A
  • SEC31d
    SEC Form DEFA14A filed by Halozyme Therapeutics Inc.
  • SEC31d
    SEC Form DEF 14A filed by Halozyme Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022